ZIOPHARM OncologyClinical Trials




Clinical Trials


darinaparsin (ZIO-101)» More On These Trials

Darinaparsin is a novel and proprietary form of organic arsenic. It is in a late Phase II trial in patients with primary liver cancer, advanced myeloma and patients with diverse hematological malignancies, and a Phase I trial has also begun involving oral administration.

For patients and healthcare professionals interested in more information about ZIOPHARM clinical trials, please contact info@ziopharm.com or call 617-259-1983.



palifosfamide (ZIO-201)» More On These Trials

Palifosfamide is a stabilized IPM (isophosphoramide mustard). A Phase II clinical trial in sarcoma is nearing completion, and a Phase I/II sarcoma combination trial is now underway.

For patients and healthcare professionals interested in more information about ZIOPHARM clinical trials, please contact info@ziopharm.com or call 617-259-1983.



indibulin (ZIO-301)» More On These Trials

Indibulin is a novel, oral synthetic anti-mitotic agent related to but with a different mechanism than other tubulin-binding drugs that include the widely used taxanes and the vinca alkaloids. Importantly, there has been no neurotoxicity reported, a common and problematic adverse event usually associated with tubulin-binding agents. Indibulin is currently in a late Phase I trial in Europe and the United States, and a Phase I/II combination trial has been initiated.

For patients and healthcare professionals interested in more information about ZIOPHARM clinical trials, please contact info@ziopharm.com or call 617-259-1983.
Helpful Links

© 2008 ZIOPHARM Oncology, Inc.